Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer

Shang, Guan-Hong; Jia, Chong-Qi; Tian, Hui; Xiao, Wei; Liu, Yu; Wang, Aihua; Dong, Liang; Dong, Lin

doi:10.1016/j.rmed.2009.05.019

Cited by 73 publications

(64 citation statements)

References 21 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Discussionmentioning

confidence: 98%

“…3,7,25 HMGB1 levels have been found to be significantly increased in patients with lung cancer than those in patients with COPD and controls. 3 Furthermore, the expression of HMGB1 was correlated with the progression of non-small cell lung cancer. 25 Moreover, overexpression of HMGB1 could induce MMP9 expression and result in increased invasiveness were washed in 5% skim milk in phosphate buffered saline plus 0.03% Tween 20 (PBST) for 1 h in order to block nonspecific protein binding sites on the membrane.…”

Section: Discussionmentioning

confidence: 98%

“…Although lung cancer has long been an active area of investigation, the reason of the extraordinarily aggressive biological behavior of this tumor still remains unclear. 3,23 Our previous studies demonstrated that TLR9 response to CpG ODN in 95D cells resulted to their enhanced progression in vitro and in vivo. [14][15][16][17] It is worthwhile because CpG ODN was currently utilized as an adjuvant in antitumor immunity.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4] HMGB1 has been implicated in a variety of biologically important processes, including transcription, DNA repair, differentiation, development and extracellular signaling. [5][6][7] When released actively by immune cells or passively by necrotic cells to extracellular environment, HMGB1 could functional as pro-inflammatory mediators lead to the recruitment of inflammatory cells and the release of pro-inflammatory cytokines including TNFα, IL-1β and IL-6 via binding to the receptor for advanced glycation end products (RAGE), Toll-like receptor (TLR) 2 and/or TLR4.…”

Section: Introductionmentioning

confidence: 99%

“…[10][11][12][13] Upregulated expression of HMGB1 has been found in many tumor types including lung cancer. 3 However, high-mobility group box 1 (hMGB1) has been implicated in a variety of biologically important processes, including transcription, DNa repair, differentiation, development and extracellular signaling. however, the potential role of hMGB1 in tumor biology still remains intractable.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells

Wang

Fei

Liu

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells

Wang

Fei

Liu

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

General information/AASLD Awards

2010

Hepatology

View full text Add to dashboard Cite

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

Fahmueller¹,

Nagel²,

Hoffmann

et al. 2013

Intl Journal of Cancer

View full text Add to dashboard Cite

Radioembolization therapy (RE) is an efficient locoregional treatment for liver metastases from colorectal cancer. Serum biomarkers involved in immunogenic cell death are potentially valuable for early predicting therapy response and estimating prognosis. In a prospective observation study, blood samples were taken from 49 consecutive colorectal cancer patients with extensive hepatic metastases before, 24 and 48 hr after RE. Serum levels of high mobility group box 1 (HMGB1), receptor of glycation end products (RAGE) and activity of desoxyribonuclease were compared with response to therapy regularly determined radiologically 3 months after therapy and with overall survival. Serum levels of HMGB1 were increased already 24 hr after RE, while RAGE levels were decreased and DNAse remained unchanged. In radiological staging, 35 patients demonstrated disease progression while 14 patients had stable disease or remission. Serum HMGB1 levels 24 hr after RE were significantly higher in progressive than in nonprogressive patients while for RAGE and DNAse no difference was observed between the response groups. Concerning overall survival, high pretherapeutic (0 hr) and 24 hr levels of HMGB1 were associated with poor outcome. Multivariate analysis including HMGB1, tumor, liver and inflammation markers revealed HMGB1 and CRP as independent prognostic parameters. HMGB1 is a valuable serum biomarker for early estimation of therapy response and prognosis in colorectal cancer patients with liver metastases undergoing RE therapy.Liver metastases are detected in 15-20% of colorectal cancer patients-the third most common cancer worldwide-at time of first diagnosis and in another 15-20% during the further course of disease.1,2 Presence of metastases is associated with a poor 5-year survival rate of 12%.3 Curative surgical resection of hepatic metastases is only possible in less than 25% of colorectal cancer patients. 4 For other patients, new local therapies like radiofrequency ablation (RFA), cryotherapy, and microwave ablation are promising approaches. However, local diameter of liver lesions considerably influences recurrence rates. In particular, lesion sizes of more than 4 cm are associated with worse outcome.5 While RFA and cryotherapy cannot be performed if disseminated liver metastases are present, radioembolization therapy (RE) is a potentially valuable alternative to systemic chemotherapy in those cases. 6 As liver metastases tend to obtain their blood supply from the hepatic artery rather than from the portal vein, microspheres loaded with Yttrium 90 administered through the hepatic artery directly damage the tumor and relatively spare the radiation sensible liver tissue. 7,8 Thereby an average tumor dosage of 200-300 Gy is applied 9 to the tumor which is almost the tenfold dose as it would be possible with external beam radiation.

show abstract

Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer

Abstract: Our study suggests that HMGB1 may be a useful clinical marker for evaluating the NSCLC progression and is of potential prognostic value.

Cited by 73 publications

References 21 publications

HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells

HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells

General information/AASLD Awards

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients

Contact Info

Product

Resources

About